Kamada says KedRAB supply holds steady as CDC flags jump in US rabies exposures
K
KMDA• KedRAB supply and U.S. rabies exposure trends
- Kamada confirmed sufficient U.S. supply of KedRAB despite a CDC-cited year-over-year rise in rabies exposures and PEP use.
Inventory and manufacturing capacity positioned to avoid disruption as utilization increases, supported by a vertically integrated supply chain.KedRAB is one of two FDA-approved human rabies immune globulin products in a U.S. market estimated at USD 200 million annually.•
Kamada says KedRAB supply holds steady as CDC flags jump in US rabies exposures - KMDA News | Rallies